Jan 10 (Reuters) - AbbVie said on Tuesday it expects combined peak sales of plaque psoriasis drug Skyrizi and anti-inflammatory medicine Rinvoq to exceed $21 billion in 2027. (Reporting by Leroy Leo in Bengaluru; Editing by Shinjini Ganguli)